M Cecilia Berin1, Charuta Agashe2, A Wesley Burks3, David Chiang2, Wendy F Davidson4, Peter Dawson4, Alexander Grishin2, Alice K Henning5, Stacie M Jones6, Edwin H Kim3, Donald Y M Leung7, Madhan Masilamani2, Amy M Scurlock6, Scott H Sicherer2, Robert A Wood8, Hugh A Sampson2. 1. Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: cecilia.berin@mssm.edu. 2. Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY. 3. Department of Medicine and Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC. 4. National Institutes of Health/National Institutes of Allergy and Infectious Diseases, Bethesda, Md. 5. Emmes, Rockville, Md. 6. Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Ark. 7. Department of Pediatrics, National Jewish Health, Denver, Colo. 8. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Md.
Abstract
BACKGROUND: Allergen-specific IL-4+ and IL-13+ CD4+ cells (type 2 cells) are essential for helping B cells to class-switch to IgE and establishing an allergic milieu in the gastrointestinal tract. The role of T cells in established food allergy is less clear. OBJECTIVE: We examined the food allergen-specific T-cell response in participants of 2 food allergen immunotherapy trials to assess the relationship of the T-cell response to clinical phenotypes, including response to immunotherapy. METHODS: Blood was obtained from 84 participants with peanut allergy and 142 participants with egg allergy who underwent double-blind placebo-controlled food challenges. Peanut- and egg-responsive T cells were identified by CD154 upregulation after stimulation with the respective extract. Intracellular cytokines and chemokine receptors were also detected. The response to peanut epicutaneous immunotherapy (Peanut Epicutaneous Phase II Immunotherapy Clinical Trial [CoFAR6]; 49 participants receiving epicutaneous immunotherapy) and egg oral immunotherapy or a baked egg diet (Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy [CoFAR7]; 92 participants) was monitored over time. RESULTS: Peanut-specific type 2 and CCR6+ T cells were negatively correlated with each other and differently associated with immune parameters, including specific IgE level and basophil activation test result. At baseline, type 2 cells, but not CCR6+ cells, were predictive of clinical parameters, including a successfully consumed dose of peanut and baked egg tolerance. Exposure to peanut or egg immunotherapy was associated with a decrease in type 2 cell frequency. At baseline, high egg-specific type 2 cell frequency was the immune feature most predictive of oral immunotherapy failure. CONCLUSION: Food-specific type 2 T cells at baseline are informative of threshold of reactivity and response to immunotherapy.
BACKGROUND: Allergen-specific IL-4+ and IL-13+ CD4+ cells (type 2 cells) are essential for helping B cells to class-switch to IgE and establishing an allergic milieu in the gastrointestinal tract. The role of T cells in established food allergy is less clear. OBJECTIVE: We examined the food allergen-specific T-cell response in participants of 2 food allergen immunotherapy trials to assess the relationship of the T-cell response to clinical phenotypes, including response to immunotherapy. METHODS: Blood was obtained from 84 participants with peanut allergy and 142 participants with egg allergy who underwent double-blind placebo-controlled food challenges. Peanut- and egg-responsive T cells were identified by CD154 upregulation after stimulation with the respective extract. Intracellular cytokines and chemokine receptors were also detected. The response to peanut epicutaneous immunotherapy (Peanut Epicutaneous Phase II Immunotherapy Clinical Trial [CoFAR6]; 49 participants receiving epicutaneous immunotherapy) and egg oral immunotherapy or a baked egg diet (Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy [CoFAR7]; 92 participants) was monitored over time. RESULTS: Peanut-specific type 2 and CCR6+ T cells were negatively correlated with each other and differently associated with immune parameters, including specific IgE level and basophil activation test result. At baseline, type 2 cells, but not CCR6+ cells, were predictive of clinical parameters, including a successfully consumed dose of peanut and baked egg tolerance. Exposure to peanut or egg immunotherapy was associated with a decrease in type 2 cell frequency. At baseline, high egg-specific type 2 cell frequency was the immune feature most predictive of oral immunotherapy failure. CONCLUSION: Food-specific type 2 T cells at baseline are informative of threshold of reactivity and response to immunotherapy.
Authors: Caspar Ohnmacht; Joo-Hong Park; Sascha Cording; James B Wing; Koji Atarashi; Yuuki Obata; Valérie Gaboriau-Routhiau; Rute Marques; Sophie Dulauroy; Maria Fedoseeva; Meinrad Busslinger; Nadine Cerf-Bensussan; Ivo G Boneca; David Voehringer; Koji Hase; Kenya Honda; Shimon Sakaguchi; Gérard Eberl Journal: Science Date: 2015-07-09 Impact factor: 47.728
Authors: M Cecilia Berin; Alexander Grishin; Madhan Masilamani; Donald Y M Leung; Scott H Sicherer; Stacie M Jones; A Wesley Burks; Alice K Henning; Peter Dawson; Joanna Grabowska; Charuta Agashe; Wendy F Davidson; Robert A Wood; Hugh A Sampson Journal: J Allergy Clin Immunol Date: 2018-03-05 Impact factor: 10.793
Authors: Alyssa Mitson-Salazar; Yuzhi Yin; Daniel L Wansley; Michael Young; Hyejeong Bolan; Sarah Arceo; Nancy Ho; Christopher Koh; Joshua D Milner; Kelly D Stone; Stephen A Wank; Calman Prussin Journal: J Allergy Clin Immunol Date: 2015-10-01 Impact factor: 10.793
Authors: Magali Noval Rivas; Oliver T Burton; Petra Wise; Louis-Marie Charbonnier; Peter Georgiev; Hans C Oettgen; Rima Rachid; Talal A Chatila Journal: Immunity Date: 2015-03-10 Impact factor: 31.745
Authors: Stacie M Jones; Laurent Pons; Joseph L Roberts; Amy M Scurlock; Tamara T Perry; Mike Kulis; Wayne G Shreffler; Pamela Steele; Karen A Henry; Margaret Adair; James M Francis; Stephen Durham; Brian P Vickery; Xiaoping Zhong; A Wesley Burks Journal: J Allergy Clin Immunol Date: 2009-07-03 Impact factor: 10.793
Authors: Bert Ruiter; Neal P Smith; Brinda Monian; Ang A Tu; Elizabeth Fleming; Yamini V Virkud; Sarita U Patil; Charles A Whittaker; J Christopher Love; Wayne G Shreffler Journal: J Allergy Clin Immunol Date: 2019-10-22 Impact factor: 10.793
Authors: J A Wisniewski; S P Commins; R Agrawal; K E Hulse; M D Yu; J Cronin; P W Heymann; A Pomes; T A Platts-Mills; L Workman; J A Woodfolk Journal: Clin Exp Allergy Date: 2015-07 Impact factor: 5.018
Authors: Amy M Scurlock; A Wesley Burks; Scott H Sicherer; Donald Y M Leung; Edwin H Kim; Alice K Henning; Peter Dawson; Robert W Lindblad; M Cecilia Berin; Christine B Cho; Wendy F Davidson; Marshall Plaut; Hugh A Sampson; Robert A Wood; Stacie M Jones Journal: J Allergy Clin Immunol Date: 2020-12-05 Impact factor: 10.793
Authors: Jungang Xie; Larisa C Lotoski; Rishma Chooniedass; Ruey-Chyi Su; F Estelle R Simons; Joel Liem; Allan B Becker; Jude Uzonna; Kent T HayGlass Journal: PLoS One Date: 2012-10-11 Impact factor: 3.240